Overview
- Sasse, who spoke on a New York Times podcast Thursday, said he is about 99 days past his three-to-four-month prognosis.
- He is in an MD Anderson trial of daraxonrasib from Revolution Medicines, reporting a 76% drop in tumor volume and about 80% less pain.
- He described severe side effects, including impaired skin regrowth and bleeding that left dried blood on his face.
- He said the cancer has spread too widely to be cured even with the drug’s early gains.
- He reflected on the weight of missing his children’s milestones and said his Christian faith gives him peace.